Dandelion Research

Using AI + RWD to Measure GLP-1’s Real-World Cardioprotective Benefits

Recent research has demonstrated that GLP-1s can significantly reduce the risk of a major adverse cardiac event (MACE) in overweight or obese patients with pre-existing severe cardiovascular disease (CVD). However, it is unclear whether the cardioprotective benefits of GLP-1s extend to patients with CVD who haven't yet experienced a MACE. This first-of-its-kind study used a novel AI algorithm applied to real-world patient data to assess whether GLP-1s may have cardioprotective effects in this “clinically silent” population of more than 40 million patients in the US alone. Download our whitepaper to learn more.

Harnessing AI + Real-World Data to Unlock Novel Research Insights

We are at the brink of a fundamental shift to transform clinical research and development. This is due to the emergence of two trends that together create conditions ripe for scientific discovery.

  • Real-world data (RWD): The availability of large, multimodal clinical datasets

  • AI: The proliferation of clinical AI tools to extract insights from these datasets

In order to understand how impactful the combination of AI with multimodal RWD could be, Dandelion investigated the following research question yet-unstudied in clinical trials:

Can GLP-1s serve as a primary prevention tool to reduce the risk of heart attacks and strokes among those who do not yet suffer from severe cardiovascular disease?

This question would ordinarily require a substantial clinical trial and a long time period to arrive at a satisfactory answer. By combining the raw biological and outcomes data available in the Dandelion dataset, with a validated AI algorithm that assesses cardiovascular risk, we arrived at an answer in a matter of weeks.

To read the full research study, download the research whitepaper today.

Download the Research Whitepaper

We are committed to your privacy. Dandelion Health may use the information you provide us to contact you about our relevant content, product, and services. You may unsubscribe from these communications at any time.